May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
July 2022 in “British Journal of Dermatology” 116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
July 2022 in “British Journal of Dermatology” 53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
4 citations
,
March 2012 in “Annals of oncology” New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
November 2022 in “Journal of Investigative Dermatology” EGFR is crucial for preventing hair follicle inflammation and hair loss.
39 citations
,
March 2009 in “Dermatology Online Journal” Understanding EGFR roles could lead to new hair loss treatments.
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
20 citations
,
July 2013 in “PLoS ONE” Targeting EGFR may help reduce hair loss from chemotherapy.
March 2009 in “Dermatology Online Journal” Manipulating EGFR signaling may help treat hair loss and promote hair growth.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking EGFR can lead to hair loss due to inflammation and stem cell damage.
97 citations
,
June 2013 in “Journal of Dermatological Science” Understanding EGFR's role in skin is crucial for better treatments and managing side effects.
3 citations
,
May 2019 in “Journal of Cosmetic Dermatology” Pro-Ile could be used in cosmetics to improve skin, hair growth, and healing.
32 citations
,
January 2010 in “Journal of Dermatological Science” Reduced EGFR signaling delays hair cycle and reduces fat growth, but hair development remains normal.
August 1994 in “Journal of dermatological science” Different substances affect hair and skin cell growth in various ways.
1 citations
,
July 2024 in “British Journal of Dermatology” Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.
6 citations
,
December 2023 in “Journal of Molecular Cell Biology” Removing Gsdma1/2/3 genes reduces skin cell overgrowth by blocking a specific cell pathway.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
April 2026 in “International Journal of Clinical Oncology” Combining immune checkpoint inhibitors with other cancer therapies increases skin side effects in Asian patients.
September 2019 in “Journal of Investigative Dermatology” EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.
29 citations
,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
36 citations
,
January 2012 in “Dermatology” Stopping gefitinib improved scalp condition in a woman with lung cancer.
3 citations
,
January 2011 in “Annals of Dermatology” Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
July 2023 in “Dermatology practical & conceptual” Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
September 2016 in “Journal of dermatological science” Collagen XVII is crucial for skin cell growth and nail health.
2 citations
,
June 2005 in “Clinical Oncology” A man's bald spot grew hair after starting cancer treatment with gefitinib.
62 citations
,
July 1993 in “Journal of Investigative Dermatology” Hair growth is influenced by interactions between skin layers, growth factors, and hormones, but the exact mechanisms are not fully understood.